Fig. 4From: Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysisPooled hazard ratios with 95% CI for event-free survival of neoadjuvant chemotherapy plus immune checkpoint inhibitors versus neoadjuvant chemotherapy in the overall populationsBack to article page